The Zhitong Finance App learned that on Tuesday, TEVA.US (TEVA.US) rose more than 4% to 42.65 US dollars, and its stock price reached a record high. According to the news, Teva Pharmaceuticals announced financial results for the third quarter of 2026. The company's non-GAAP earnings per share were 0.86 US dollars, exceeding market expectations of 0.14 US dollars; revenue was 4.4 billion US dollars, down 2% year on year, exceeding market expectations of 170 million US dollars.

Innovative pharmaceuticals AUSTEDO, AJOVY, and UZEDY achieved total revenue of about 1.1 billion US dollars, an increase of 33% year-on-year based on a fixed exchange rate. Teva raised the 2026 revenue forecasts for the three major brands. By product, according to fixed exchange rates, AUSTEDO's revenue increased 21% year over year to US$751 million; AJOVY's revenue increased 61% to US$269 million; and UZEDY's revenue increased 96% to US$85 million. Excluding the US$500 million duvakitug milestone payment in the fourth quarter of 2025, non-GAAP gross margin increased 345 basis points year over year to 58.7%, a record high in a single quarter in ten years.

The company disclosed its financial guidance for the 2026 fiscal year: revenue of US$167-17 billion, with market expectations of US$16.66 billion; non-GAAP diluted earnings per share of US$1.92-2.11; general market expectations of US$2.09; adjusted EBITDA of US$4.23-4.43 billion; and free cash flow of US$21-2.4 billion.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.